Aravive, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARAV research report →
Companyaravive.com
Aravive, Inc. , a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma.
- CEO
- Fredric N. Eshelman
- IPO
- 2014
- Employees
- 23
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $2.95M
- P/E
- -0.02
- P/S
- 0.32
- P/B
- 0.14
- EV/EBITDA
- 0.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -632.60%
- Op Margin
- -775.28%
- Net Margin
- -885.64%
- ROE
- -306.06%
- ROIC
- -161.69%
Growth & Income
- Revenue
- $9.14M · 22.78%
- Net Income
- $-80,921,000 · -112.17%
- EPS
- $-2.22 · -16.84%
- Op Income
- $-70,837,000
- FCF YoY
- -102.29%
Performance & Tape
- 52W High
- $2.46
- 52W Low
- $0.04
- 50D MA
- $0.10
- 200D MA
- $0.59
- Beta
- 2.19
- Avg Volume
- 2.24M
Get TickerSpark's AI analysis on ARAV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 23 | Petrini Maria Carolina | other | 400,000 |
| Apr 10, 23 | Petrini Maria Carolina | other | 0 |
| Feb 1, 23 | McIntyre Gail Frances | other | 700,000 |
| Feb 1, 23 | Geller Robert B. | other | 400,000 |
| Feb 1, 23 | HOWARD RUDY | other | 400,000 |
| Feb 1, 23 | Dove Leonard Scott | other | 400,000 |
| Oct 24, 22 | Ho Peter Tai-Ching | other | 54,353 |
| Oct 24, 22 | Zhang Eric | other | 271,769 |
| Oct 24, 22 | Zhang Eric | other | 271,768 |
| Oct 24, 22 | Giaccia Amato | other | 271,768 |
Our ARAV Coverage
We haven't published any research on ARAV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARAV Report →